NAPLEX Quiz: Prescription Regulations And Safety Warnings

What this quiz covers

This quiz focuses on Prescription Regulations And Safety Warnings, giving you a quick way to practice the rules, question types, and explanations that matter most for NAPLEX.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

Question 1

1. A DATA 2000 X-waiver number must be written on the prescription for it to be valid
2. It must be prescribed on the official state triplicate form used for Schedule II medications
3. It is a Schedule III controlled substance and may be refilled up to 5 times within 6 months under federal law (correct answer)
4. It cannot be e-prescribed and must be handwritten to be legally dispensed

Explanation: This question tests knowledge of federal controlled substance regulations for buprenorphine/naloxone prescriptions. Buprenorphine/naloxone is a Schedule III controlled substance used for opioid use disorder treatment. The correct answer (C) identifies that as a Schedule III controlled substance, it may be refilled up to 5 times within 6 months from the date written under federal law. Option A is incorrect because the DATA 2000 X-waiver requirement was eliminated in January 2023 - prescribers no longer need a special waiver number to prescribe buprenorphine for opioid use disorder. Option B is wrong because Schedule III medications do not require triplicate forms (this applies to Schedule II in some states). Option D is incorrect because buprenorphine/naloxone can be e-prescribed like other controlled substances with appropriate security measures. The clinical pearl is that recent regulatory changes have removed the X-waiver requirement to increase access to buprenorphine treatment, but standard controlled substance regulations still apply including refill limitations and prescription monitoring program requirements.

Question 2

1. Dispense as written; daily methotrexate is standard for rheumatoid arthritis
2. Clarify with the prescriber because methotrexate for rheumatoid arthritis is typically dosed weekly, not daily (correct answer)
3. Change to methotrexate 15 mg by mouth twice daily to simplify the regimen
4. Advise the patient to stop folic acid because it reduces methotrexate efficacy

Explanation: This question tests recognition of a potentially fatal medication error involving methotrexate dosing frequency. The prescription calls for daily methotrexate for rheumatoid arthritis, which is a serious prescribing error as methotrexate for RA is dosed weekly, not daily. The correct answer (B) requires clarification with the prescriber because daily dosing of methotrexate can cause severe toxicity including bone marrow suppression, hepatotoxicity, and potentially fatal outcomes. Option A is dangerously incorrect - daily methotrexate is never standard for rheumatoid arthritis and has led to numerous deaths. Option C is wrong because it perpetuates the daily dosing error and increases the total dose even further. Option D is incorrect because folic acid supplementation is actually recommended with methotrexate to reduce side effects, not contraindicated. The clinical pearl is that methotrexate for non-oncologic indications (RA, psoriasis) must be dosed weekly, and pharmacists should always verify dosing frequency to prevent this common but potentially fatal error. Many institutions require special labeling and counseling emphasizing "WEEKLY" dosing.

Question 3

1. Dispense only after confirming enrollment and authorization in the iPLEDGE REMS and documenting required pregnancy prevention requirements (correct answer)
2. Require a written prescription with a prescriber's manual signature because isotretinoin is a Schedule II controlled substance
3. Limit dispensing to a 7-day supply because isotretinoin has a boxed warning for dependence
4. Dispense only if the patient signs an opioid treatment agreement and receives naloxone

Explanation: This question tests the regulatory requirements under the iPLEDGE REMS program for isotretinoin due to its high teratogenic risk. The key patient-specific factor is the female patient's childbearing potential, as she is 28 years old and on oral contraceptives. Choice A is the best action because isotretinoin dispensing requires confirmation of iPLEDGE enrollment, authorization, and documentation of pregnancy prevention to ensure compliance and prevent fetal exposure. Choice B is incorrect because isotretinoin is not a Schedule II controlled substance, and choice C is wrong as it has no boxed warning for dependence nor a 7-day supply limit; choice D is suboptimal as isotretinoin is not an opioid requiring naloxone or treatment agreements. Pharmacists must always verify iPLEDGE requirements before dispensing teratogenic medications like isotretinoin. A useful framework is to check for REMS programs when handling high-risk drugs, prioritizing patient safety through regulatory adherence.

Question 4

1. Counsel that the medication must be stored in the refrigerator and discarded after 14 days
2. Assess bleeding risk and counsel on signs of bleeding and the importance of adherence to avoid recurrent thrombosis (correct answer)
3. Dispense only after verifying enrollment in a REMS program requiring weekly laboratory monitoring
4. Warn that abrupt discontinuation is safe because rebound thrombosis does not occur with direct oral anticoagulants

Explanation: This question assesses safety warnings for direct oral anticoagulants like rivaroxaban, focusing on bleeding and adherence. The key patient-specific factor is the patient's recent pulmonary embolism and normal renal function, necessitating vigilant monitoring. Choice B is the best because it emphasizes assessing bleeding risk and counseling on signs of bleeding plus adherence to prevent recurrent thrombosis, aligning with boxed warnings. Choice A is incorrect as rivaroxaban is stable at room temperature; choice C is wrong because rivaroxaban has no REMS requiring weekly labs; choice D is suboptimal as abrupt discontinuation can cause rebound thrombosis. A clinical pearl is to always counsel on bleeding precautions with anticoagulants. Use a framework of evaluating drug-specific risks like bleeding versus thrombosis when dispensing high-risk medications.

Question 5

1. The prescription may be refilled up to 11 times within 12 months if used for chronic pain
2. Refills are not permitted for this medication; a new prescription is required for additional quantities (correct answer)
3. Refills are permitted if the prescriber includes a diagnosis code on the prescription
4. The pharmacist may add refills after contacting the prescriber's office staff without prescriber authorization

Explanation: This question evaluates federal controlled substance regulations for Schedule II opioids like hydrocodone/acetaminophen. The key patient-specific factor is the patient's age of 67 and chronic pain from osteoarthritis, which may warrant long-term management but must comply with refill restrictions. Choice B is the best because Schedule II medications cannot have refills, requiring new prescriptions to prevent abuse and ensure oversight. Choice A is incorrect as it applies to Schedule III-V substances, not II; choice C is wrong because diagnosis codes do not authorize refills for Schedule II; choice D is suboptimal as pharmacists cannot add refills without direct prescriber authorization. Always verify controlled substance schedules when assessing prescription validity. A decision framework for opioids involves checking for red flags like high quantities and ensuring compliance with DEA rules to mitigate diversion risks.

Question 6

1. Start metformin at a lower dose (e.g., 500 mg once or twice daily) and titrate to reduce gastrointestinal intolerance (correct answer)
2. Change to metformin 2000 mg by mouth three times daily for faster glycemic control
3. Discontinue hydrochlorothiazide immediately because it is contraindicated with metformin
4. Dispense as written because metformin must be initiated at 1000 mg twice daily in all adults

Explanation: This question assesses safety considerations for initiating metformin, emphasizing gastrointestinal tolerance. The key patient-specific factor is the patient's new diabetes diagnosis and normal renal function, allowing titration. Choice A is the best because starting low and titrating minimizes GI side effects, promoting adherence and safety. Choice B is incorrect as higher dosing increases intolerance; choice C is wrong because no contraindication exists; choice D is suboptimal as initiation at 1000 mg bid is not mandatory. Start metformin low to go slow for tolerance. A framework involves evaluating patient-specific factors like tolerance risks when adjusting doses.

Question 7

1. Methadone for opioid use disorder may be prescribed and dispensed from any outpatient pharmacy without restriction
2. Methadone for opioid use disorder maintenance is generally restricted to opioid treatment programs; verify indication and prescriber/setting appropriateness before dispensing (correct answer)
3. Methadone is not a controlled substance, so no additional verification is needed
4. Methadone prescriptions must include two patient identifiers and the patient's driver's license number to be valid

Explanation: This question evaluates regulatory restrictions on methadone dispensing for opioid use disorder maintenance. The key patient-specific factor is the patient's opioid use disorder and existing methadone from an opioid treatment program, indicating a controlled setting. Choice B is the best because methadone for OUD is restricted to certified programs, requiring verification to prevent improper dispensing and ensure compliance. Choice A is incorrect as outpatient pharmacies cannot dispense it for OUD without restrictions; choice C is wrong because methadone is Schedule II; choice D is suboptimal as it misapplies identification requirements. Verify prescriber and setting for restricted opioids. A framework involves confirming indication and regulatory allowances for controlled substances in addiction treatment.

Question 8

1. Dispense as written; there is no maximum daily dose for acetaminophen in liver disease
2. Counsel to avoid all acetaminophen and substitute ibuprofen without prescriber involvement
3. Clarify and counsel on a reduced maximum daily acetaminophen dose in chronic liver disease (e.g., do not exceed 2,000 mg/day) and avoid duplicate products (correct answer)
4. Recommend increasing dose to 3 tablets every 4 hours to overcome reduced hepatic activation

Explanation: This question examines acetaminophen safety warnings in liver disease, focusing on dose limits. The key patient-specific factor is the patient's compensated cirrhosis with elevated liver markers, increasing toxicity risk. Choice C is the best because clarifying a reduced daily limit like 2g and avoiding duplicates prevents hepatotoxicity. Choice A is incorrect as limits are needed; choice B is wrong because ibuprofen may worsen liver issues; choice D is suboptimal as increasing dose heightens risks. Limit acetaminophen to 2g/day in liver disease. A framework involves assessing organ function and adjusting doses for hepatotoxic drugs.

Question 9

1. Refills are permitted up to 5 times within 6 months because this is a Schedule III stimulant
2. Refills are not permitted for Schedule II medications; a new prescription is required for each fill (correct answer)
3. The pharmacist may transfer this prescription to another pharmacy one time because it is a controlled substance
4. The prescription is invalid unless it includes the patient's diagnosis and ICD-10 code

Explanation: This question tests controlled substance regulations for Schedule II stimulants like amphetamine/dextroamphetamine. The key patient-specific factor is the young adult's ADHD, requiring strict oversight to prevent misuse. Choice B is the best because no refills are allowed for Schedule II, ensuring compliance and reducing diversion. Choice A is incorrect as it applies to Schedule III; choice C is wrong because transfers are limited; choice D is suboptimal as diagnosis codes are not required for validity. Verify no refills on Schedule II prescriptions. A framework is to confirm schedule and refill rules for all controlled substances.

Question 10

1. Refills are prohibited because albuterol nebulizer solution is a Schedule III controlled substance
2. Refills are permitted, but the pharmacist should ensure the prescription includes directions and quantity; excessive refills may warrant clinical follow-up for overuse (correct answer)
3. Albuterol requires a REMS program enrollment prior to dispensing
4. Albuterol prescriptions must be written on tamper-resistant paper to be valid

Explanation: This question evaluates regulatory requirements for non-controlled medications like albuterol, focusing on refill appropriateness. The key patient-specific factor is the patient's COPD and potential overuse with 12 refills, signaling possible poor control. Choice B is the best because refills are allowed but require complete prescriptions, with follow-up for excessive use to ensure safety. Choice A is incorrect as albuterol is not Schedule III; choice C is wrong because it has no REMS; choice D is suboptimal as tamper-resistant paper is for controlled substances. Monitor refill frequency for rescue inhalers. A framework is to assess clinical appropriateness beyond legal validity for chronic therapies.

Question 11

1. Dispense isotretinoin today if the patient signs a general pregnancy warning form at the pharmacy
2. Dispense isotretinoin and counsel to add St. John's wort to improve mood while on therapy
3. Hold dispensing until iPLEDGE requirements are verified and counsel to stop doxycycline and vitamin A supplements (correct answer)
4. Change isotretinoin to tretinoin 0.1% cream because oral isotretinoin is contraindicated in all women of childbearing potential

Explanation: This question tests knowledge of iPLEDGE REMS requirements for isotretinoin dispensing. The patient is a woman of childbearing potential starting isotretinoin, which requires strict adherence to the iPLEDGE program due to severe teratogenicity. The correct answer (C) is best because isotretinoin cannot be dispensed until all iPLEDGE requirements are verified (including registration, two forms of contraception, negative pregnancy tests, and counseling), and the patient must discontinue vitamin A supplements (which can cause additive toxicity) and doxycycline (which can increase intracranial pressure when combined with isotretinoin). Option A is incorrect because a general pregnancy warning form is insufficient - iPLEDGE has specific requirements that must be met before dispensing. Option B is dangerous because St. John's wort can reduce oral contraceptive effectiveness, potentially leading to pregnancy while on isotretinoin. Option D is incorrect because isotretinoin is not contraindicated in all women of childbearing potential - it can be used with proper iPLEDGE compliance. The clinical pearl is that isotretinoin dispensing requires verification of iPLEDGE registration and compliance before any doses can be dispensed, and pharmacists must counsel on drug interactions that could compromise contraception or increase toxicity.

Question 12

1. Transdermal fentanyl is appropriate for opioid-naïve patients when pain is chronic
2. Transdermal fentanyl should be initiated only in opioid-tolerant patients due to risk of fatal respiratory depression (correct answer)
3. The patch should be cut in half if the patient feels overly sedated
4. The patch should be applied every 24 hours to avoid end-of-dose failure

Explanation: This question tests knowledge of the FDA boxed warning for transdermal fentanyl regarding opioid tolerance requirements. The patient is essentially opioid-naïve, using only 1-2 tablets of immediate-release oxycodone 5 mg per week, which falls far below the opioid tolerance threshold. The correct answer (B) identifies that transdermal fentanyl should only be initiated in opioid-tolerant patients (defined as ≥60 mg oral morphine equivalents daily for ≥1 week) due to risk of fatal respiratory depression. Option A is incorrect because transdermal fentanyl is contraindicated in opioid-naïve patients regardless of pain chronicity. Option C is dangerous advice because fentanyl patches should never be cut as this can cause dose dumping and fatal overdose. Option D is incorrect regarding both safety (doesn't address the opioid-naïve issue) and dosing frequency (patches are changed every 72 hours, not 24 hours). The clinical pearl is that transdermal fentanyl carries a boxed warning restricting use to opioid-tolerant patients only, and pharmacists must verify opioid tolerance before dispensing to prevent fatal respiratory depression in opioid-naïve patients.

Question 13

1. Dispense clozapine immediately; ANC monitoring is optional and can be done annually
2. Verify clozapine REMS enrollment and required ANC criteria/monitoring before dispensing; contact the prescriber due to low ANC (correct answer)
3. Require a triplicate prescription form because clozapine is Schedule II
4. Hold metformin because it is contraindicated with clozapine due to hypoglycemia risk

Explanation: This question tests the pharmacist's knowledge of the Clozapine Risk Evaluation and Mitigation Strategy (REMS) program, which is required due to the drug's risk of severe neutropenia. The key patient-specific factor is the low absolute neutrophil count (ANC) of 1,200/mm³, which falls below the typical threshold of ≥1,500/mm³ for safe initiation of clozapine therapy. Verifying REMS enrollment and ANC monitoring before dispensing, and contacting the prescriber due to the low ANC, is the best action to ensure patient safety and regulatory compliance, as it prevents potential agranulocytosis and adheres to mandatory monitoring protocols. Choice A is incorrect because ANC monitoring is mandatory under REMS, not optional or annual, and dispensing without verification could endanger the patient. Choice C is suboptimal as clozapine is not a Schedule II controlled substance requiring a triplicate form, and choice D is wrong because there is no contraindication between metformin and clozapine regarding hypoglycemia risk; they can be used together with appropriate monitoring. A key clinical pearl is that pharmacists must always confirm REMS requirements for high-risk medications like clozapine to mitigate life-threatening adverse effects. When evaluating such prescriptions, use a framework that prioritizes verifying patient eligibility, lab values, and prescriber communication before dispensing.

Question 14

1. Paroxetine is preferred in pregnancy because it reduces risk of congenital cardiac malformations
2. Paroxetine is associated with fetal risk; the pharmacist should contact the prescriber to consider an alternative SSRI with a better pregnancy safety profile (correct answer)
3. Paroxetine requires dispensing only through a REMS program due to risk of aplastic anemia
4. Paroxetine must be dispensed in a child-resistant blister pack by federal law

Explanation: This question tests pregnancy-related safety warnings for SSRIs like paroxetine, which carries a risk of fetal cardiac malformations. The key patient-specific factor is the patient's 10-week pregnancy, heightening teratogenic concerns. Choice B is the best because paroxetine is associated with fetal risks, prompting prescriber contact for safer alternatives like sertraline to comply with safety guidelines. Choice A is incorrect as paroxetine increases cardiac malformation risk; choice C is wrong because paroxetine has no REMS for aplastic anemia; choice D is suboptimal as no federal law mandates child-resistant blister packs for it. Always prioritize fetal safety in pregnant patients on medications. A decision framework is to review pregnancy categories and recommend alternatives when risks outweigh benefits.

Question 15

1. Dispense as written because renal impairment does not affect colchicine toxicity
2. Clarify and recommend appropriate gout flare dosing with renal impairment and avoid excessive hourly dosing due to toxicity risk (correct answer)
3. Increase colchicine frequency to every 30 minutes due to reduced renal clearance
4. Substitute indomethacin automatically without prescriber authorization because it is first-line

Explanation: This question assesses dosing safety for colchicine in renal impairment during gout flares. The key patient-specific factor is the patient's eGFR of 35 mL/min/1.73 m², increasing toxicity risk with frequent dosing. Choice B is the best because clarifying adjusted dosing prevents overdose and complications like GI toxicity. Choice A is incorrect as renal impairment affects colchicine; choice C is wrong because increasing frequency heightens risks; choice D is suboptimal as substitution requires authorization. Adjust colchicine for renal function. A framework is to verify organ function and apply dosing guidelines for accumulative drugs.

Question 16

1. Dispense as written because hives are not a true allergy and sulfonamides are always safe
2. Do not dispense; contact the prescriber for an alternative due to the patient's sulfonamide allergy history (correct answer)
3. Change to sulfadiazine automatically because it is a different sulfonamide and avoids cross-reactivity
4. Reduce the dose to once daily to prevent allergic reactions

Explanation: This question assesses allergy-related safety warnings for sulfonamides like trimethoprim/sulfamethoxazole. The key patient-specific factor is the patient's documented sulfa allergy with hives, signaling potential hypersensitivity. Choice B is the best because avoiding dispensing and suggesting alternatives prevents allergic reactions, prioritizing safety. Choice A is incorrect as hives indicate true allergy; choice C is wrong because cross-reactivity exists; choice D is suboptimal as dose reduction does not mitigate allergy. Confirm allergy details before dispensing. A framework involves verifying allergy history and assessing cross-reactivity risks.

Question 17

1. Counsel on possible neuropsychiatric symptoms and advise the patient to report mood or behavior changes (correct answer)
2. Dispense only after confirming iPLEDGE enrollment and two negative pregnancy tests
3. Avoid use because it is a Schedule II controlled substance with high diversion risk
4. Store varenicline frozen to maintain potency and discard after thawing

Explanation: This question assesses safety warnings for varenicline, including neuropsychiatric effects. The key patient-specific factor is the patient's depression history and bupropion use, potentially amplifying mood risks. Choice A is the best because counseling on reporting changes ensures early intervention and safety. Choice B is incorrect as varenicline has no iPLEDGE; choice C is wrong because it is not Schedule II; choice D is suboptimal as it requires no freezing. Monitor for psychiatric symptoms with smoking cessation aids. A framework is to review boxed warnings and counsel on monitoring signs.

Question 18

1. Dispense as written; sildenafil is safe with nitrates if doses are separated by 2 hours
2. Do not dispense and contact the prescriber because concomitant nitrates and sildenafil can cause severe hypotension (correct answer)
3. Recommend doubling sildenafil dose to 100 mg to overcome beta-blocker effects
4. Dispense only after confirming enrollment in a REMS program due to risk of dependence

Explanation: This question assesses contraindication warnings for sildenafil with nitrates. The key patient-specific factor is the patient's nitroglycerin use for angina, risking severe hypotension. Choice B is the best because not dispensing and contacting the prescriber prevents life-threatening interactions, ensuring safety. Choice A is incorrect as no safe separation exists; choice C is wrong because doubling is unsafe; choice D is suboptimal as no REMS for dependence. Contraindicated combo: PDE5 inhibitors and nitrates. A framework involves screening for absolute contraindications in drug profiles.

Question 19

1. Buprenorphine/naloxone may only be dispensed by pharmacies registered as opioid treatment programs
2. This prescription must be written on a triplicate form because it is Schedule II
3. Ensure the prescription meets controlled substance requirements for a Schedule III medication (e.g., refills allowed within federal limits) and verify prescriber legitimacy (correct answer)
4. Dispense only after confirming iPLEDGE enrollment and a negative pregnancy test

Explanation: This question evaluates regulatory requirements for Schedule III opioids like buprenorphine/naloxone for opioid use disorder. The key patient-specific factor is the patient's OUD, requiring prescriber verification for legitimacy. Choice C is the best because it ensures compliance with controlled substance rules, allowing refills while verifying authenticity. Choice A is incorrect as any pharmacy can dispense; choice B is wrong because it is Schedule III, not II; choice D is suboptimal as no iPLEDGE is needed. Verify prescriber waivers for buprenorphine. A framework involves confirming schedule, refills, and prescriber qualifications.

Question 20

1. The pharmacist may fill it because Schedule II prescriptions never expire under federal law
2. The pharmacist may add refills and fill it because it is less than 12 months old
3. The pharmacist should evaluate validity based on applicable state law and corresponding responsibility; many states limit how long after issuance a Schedule II prescription may be filled (correct answer)
4. The pharmacist must convert it to an emergency oral authorization automatically because it is older than 30 days

Explanation: This question assesses understanding of regulatory requirements for filling Schedule II controlled substance prescriptions, particularly regarding validity periods after issuance. The key factor is the prescription's age of 8 months, with no refills authorized, for oxycodone, a Schedule II opioid. Evaluating validity based on applicable state law and the pharmacist's corresponding responsibility is the best approach, as federal law does not set an expiration but many states impose limits (e.g., 6 months) to prevent abuse and ensure therapeutic necessity. Choice A is incorrect because while federal law lacks an expiration, state laws often do, and blindly dispensing could violate regulations. Choice B is suboptimal as pharmacists cannot add refills to Schedule II prescriptions, and choice D is wrong because conversion to emergency oral authorization is not automatic for outdated prescriptions and applies only in specific urgent scenarios. A transferable pearl is that for controlled substances, always cross-reference federal and state laws, prioritizing the stricter rule to promote safety and prevent diversion. In decision-making, employ a framework that includes verifying prescription date, refill status, and patient need against legal timelines before filling.